RIA
BIOT

RP Investment Advisors’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

RP Investment Advisors’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-124,469
Closed -$1.2M – 123
2021
Q2 		$1.2M Buy
+124,469
New +$1.21M 0.16% 70

Other funds holding BIOT

CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RP Investment Advisors's BIOT Position: Q3 2021 in Review

RP Investment Advisors sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q3 2021, closing a stake of 124,469 shares — an estimated $1.2M sold.

RP Investment Advisors first reported a position in BIOT in Q2 2021 and held it in 1 quarter. The position peaked at $1.2M in Q2 2021. 58 funds tracked by Wall St. Rank hold BIOT as of Q3 2021.

  • RP Investment Advisors reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q3 2021 after selling out during the quarter.
  • RP Investment Advisors sold 124,469 Biotech Acquisition Company Class A Ordinary Shares shares in Q3 2021, an estimated $1.2M.
  • RP Investment Advisors first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 1 quarter.
  • RP Investment Advisors's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.2M in Q2 2021.
  • 58 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q3 2021.

Based on RP Investment Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.